about
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapyChemical Variations on the p53 Reactivation ThemeUpdate on rational targeted therapy in AMLInducing Oncoprotein Degradation to Improve Targeted Cancer TherapyResistance and gain-of-resistance phenotypes in cancers harboring wild-type p53mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 InteractionSignificant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug TreatmentDesign, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 InteractionPrototypes of newly conceived inorganic and biological sensors for health and environmental applicationsSerum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer.Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine DoubleNew targets for the treatment of follicular lymphoma.An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomasTargeting p53 for Novel Anticancer Therapy.Phytochemicals Approach for Developing Cancer Immunotherapeutics.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.Sources of superoxide/H2O2 during mitochondrial proline oxidationUnveiling new biological relationships using shared hits of chemical screening assay pairsProfiling of protein interaction networks of protein complexes using affinity purification and quantitative mass spectrometry.A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implicationsWhole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regressionAn antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein.Growth inhibition and apoptosis induction by (+)-Cyanidan-3-ol in hepatocellular carcinoma.Inflammation and p53: A Tale of Two StressesRational design of topographical helix mimics as potent inhibitors of protein-protein interactions.MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer.Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomasDesign, synthesis and protein-targeting properties of thioether-linked hydrogen bond surrogate helicesMurine double minute-2 expression is required for capillary maintenance and exercise-induced angiogenesis in skeletal muscle.Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action.Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1
P2860
Q24651380-04F74072-433C-4C76-9A65-9EB1CCDDE5FFQ26749008-EAAF4C3F-3937-42BE-9E93-8B8D1138D3B2Q26766152-3F4ECD4B-D109-4D0C-974A-8F6CF6796859Q26782145-645FF53E-1567-4F44-AAC1-1437FEDA40FCQ27006998-BEA16B89-EBFA-4D9C-AF9B-DD789BE3CE40Q28386936-494C205D-EF35-4E67-A7BA-3D8CB3825E0CQ28548249-1941A85F-57AF-4197-AADF-014083F11130Q28548694-D1B3895F-B987-4C9A-A971-D75BF5497B30Q28708981-957AD76C-E92C-40E6-9D31-837DC5DAA9D8Q30353143-342F0176-0722-42FA-8AB1-58E2E7BEA634Q33572704-78C0D487-D32D-4F60-A27F-D83A46F11183Q33587396-B12C55EA-802B-4C56-AB88-995F6620B454Q33640890-D0C6E38B-54D0-4881-B7BE-64B132271F0FQ33655329-6EF6B0C9-8F1F-4124-A626-C09DA599C4BBQ33809573-382880A6-636E-44DA-9897-3BE93169020CQ33852683-9E610D5B-9EBC-4515-8114-9F9AECF137C4Q33997232-B8CD642C-4214-472F-A679-CFA9F72DF4D4Q34085968-5EA76D71-8757-46DE-BFC2-DE26CE30DC94Q34103220-5FDDF645-4933-4DED-9269-2C78A79A3641Q34121939-235B2EB4-C13C-4778-86B5-1E5EB57AB05CQ34361953-FA3F92FA-76F2-42BC-A841-85D6462230CAQ34365715-D2C9C8CF-151D-4D24-9183-D950675428C2Q34435519-64EEFBF7-68DA-4C2D-B01C-1E85882DF86FQ34458379-51E49A15-CE2F-4DF6-BE7F-DFE336B7F678Q34481803-2A17AE36-CDBC-42FB-B28D-1F969DCE407EQ34584722-4B9A261F-2C5F-4C81-85F9-2875D30A0F48Q34754934-BE989C01-ECB3-4B83-89AF-7C8CFEBE660CQ34873063-64CFA0C0-E73D-4564-AA8F-AD1A4DFA7467Q35103171-6EC8B802-07CC-42DE-B6E2-8E0A847A9240Q35157579-4349727B-B059-4882-9D8A-923A48FE3F5DQ35227870-88A6B483-1D19-4A9E-B43E-86DF45808401Q35290386-AF8A7771-FA2B-4F92-9177-14BE27973CC0Q35295410-37BE04F6-C73D-4F9A-8E58-8EB386ABA8F5Q35550054-8064B440-13B0-4364-99DF-CA167C163C0EQ36048192-F32069F5-A766-4D62-AACB-837A70561496Q36143734-806FC502-E84F-418E-9011-5F3483CEB0E4Q36329784-43E8FAFE-91E9-4DB4-837E-A68EEB085B0EQ36342520-CCF09EEE-C11C-4FEE-BA1E-6CE264957A43Q36356343-822E4C77-F52B-42E5-AAD5-C5008A49AC2EQ36413835-C0E7D5D0-7273-4B72-8697-E88F6F673F24
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting the MDM2-p53 interaction for cancer therapy
@en
Targeting the MDM2-p53 interaction for cancer therapy.
@nl
type
label
Targeting the MDM2-p53 interaction for cancer therapy
@en
Targeting the MDM2-p53 interaction for cancer therapy.
@nl
prefLabel
Targeting the MDM2-p53 interaction for cancer therapy
@en
Targeting the MDM2-p53 interaction for cancer therapy.
@nl
P2860
P1476
Targeting the MDM2-p53 interaction for cancer therapy
@en
P2093
Sanjeev Shangary
Shaomeng Wang
P2860
P304
P356
10.1158/1078-0432.CCR-07-5136
P407
P577
2008-09-01T00:00:00Z